News & Events about Immatics Nv.
Ticker Report
2 months ago
Surrozen (NASDAQ:SRZN Get Rating) and Immatics (NASDAQ:IMTX Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, earnings, institutional ownership, risk, ...
Globe Newswire
3 months ago
Houston, Texas and Tuebingen, Germany, October 10, 2022 Immatics N.V. (NASDAQ: IMTX, Immatics), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today that it has agreed to sell, by way of an underwritten ...
Globe Newswire
3 months ago
Company to host conference call today, October 10, at 8:30 am EDT / 2:30 pm CEST Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expressionUpdate covers data from 27 ...
Globe Newswire
4 months ago
TCER IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME In preclinical studies, IMA402 demonstrated enhanced anti-tumor activity in vivo and reduced T cell engager-associated toxicities as part of overall favorable in vitro ...